InvestorsHub Logo
Followers 6
Posts 129
Boards Moderated 0
Alias Born 12/14/2015

Re: skitahoe post# 305575

Tuesday, 09/08/2020 2:30:52 PM

Tuesday, September 08, 2020 2:30:52 PM

Post# of 708881
See the 8/19 PR below. Data lock was imminent following this PR. In addition, SNO needed data by 9/1.

My guess of the timelines:

7/24 PR: "The Company currently anticipates that the remaining analyses by these specialty service providers will be completed within the next couple weeks. When this external data joins the now locked data from the Trial sites, the overall Trial dataset will be locked."

8/19: PR (below - essentially says we have all the data). Remember,
they've had 95%+ of the data for years..
8/21ish: Data lock
8/24ish: Top line Endpoints given to company who gets it to SNO by 9/1
8/27: Accelerate Sawston buildout
8/31: Liau SNO presentation goes "live" on website
9/1: Flashworks deal
9/12: LP speaks

Question is have they met with the SAB already? Per the above, it appears that TLD could come any day but certainly within two-weeks.
What seems to be a lock is that the longer we hear nothing the more likely it is that data is positive.

Per this timeline if Data Lock was indeed on 8/21ish then the statisticians have had the data for over two weeks. Would everything that has happened - happened - if the company didn't have positive TLD?
Would Flashworks have accepted $2.01 million in company stock as part of their acquisition?




BETHESDA, Md., August 19, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the remaining outstanding clinical trial data for the Company’s Phase 3 trial of DCVax®-L for Glioblastoma brain cancer as described in the Company’s last report on July 24, 2020 has now been completed by the specialty analytics firms. With this data now in hand, final quality control checking and confirmation are under way to enable Data Lock.

This further data involves specialty analytics such as genomic profiling for IDH mutations and certain imaging. The independent CRO managing the trial is now integrating this data into the overall trial database containing the clinical data from the trial sites that was already complete and locked as reported on July 24, 2020, in order to complete the overall trial dataset.

When Data Lock is reached, the independent statisticians will be given access to the unblinded dataset. The Company will remain blinded while the statisticians make the computations, converting the mass of raw data from the trial into formal tables and listings, and survival and progression measures, to report the trial results.

As previously reported, the statisticians’ work is estimated to take a couple of weeks. When their computations are completed, the Company will receive the results of those computations and thereby become unblinded. It is anticipated that the Company’s Scientific Advisory Board, the Steering Committee of the Trial and other key medical expert advisors will likewise receive the results, and thereby become unblinded as well.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News